about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Up­dat­ed: Af­ter long slog, As­traZeneca fi­nal­ly gets CT­LA-4 drug over fin­ish line

3 years ago
Pharma
FDA+

Eli Lil­ly, Ab­b­Vie in M&A ac­tion; Gilead’s on­col­o­gy deal spree; FDA puts its foot down on Mak­e­na; and more

3 years ago
Weekly

As gov­ern­ment fund­ing dries up, Pfiz­er ex­pects to charge pri­vate pay­ers $110+ for Covid-19 vac­cine

3 years ago
Pharma
Coronavirus

Bris­tol My­ers spells out Op­di­vo win in melanoma — how does it stack up against Keytru­da?

3 years ago
R&D

Up­dat­ed: In new speed bump for Hunt­ing­ton's, FDA paus­es PTC's PhII tri­al

3 years ago
R&D
FDA+

Backed by Bob Langer, for­mer Har­vard prof sets out to test a new way to de­liv­er I/O drugs — dur­ing surgery

3 years ago
Financing
Startups

Ko­re­an buy­er jumps in­to M&A game with $566M bid for Aveo On­col­o­gy

3 years ago
Deals

In­vestors who lost mon­ey from Neil Wood­ford's fund file law­suit against in­vest­ment plat­form

3 years ago
Law

Gilead calls dibs on a PhI bis­pe­cif­ic, hands over $60M to cash-strapped Macro­Gen­ics

3 years ago
Deals

NeuBase lays off 60% of em­ploy­ees as it swaps out an­ti­sense fo­cus for gene edit­ing tech en­dorsed by George Church

3 years ago
People

BIO in tu­mult as CEO abrupt­ly ex­its; Some good PhI­II news; Da­ta is­sues still plague No­var­tis' gene ther­a­py; Hot ...

3 years ago
Weekly

Imara puts an end to its strug­gles as Or­biMed, 5AM-backed pre­ci­sion on­col­o­gy play­er rides the shell to Nas­daq

3 years ago
Deals

On Pfiz­er's heels, GSK boasts 'tru­ly ex­cep­tion­al' PhI­II da­ta for RSV vac­cine — mak­ing a bee­line to FDA

3 years ago
R&D
Pharma

Up­dat­ed: Bridge­Bio's $2.4B part­ner­ship takes a sud­den hit as Helsinn plans to with­draw NDA on FGFR2 drug

3 years ago
Deals
R&D

Now bank­rupt, Zosano sells off its drug de­liv­ery tech that once en­ticed No­vo Nordisk, Eli Lil­ly

3 years ago
Deals

Eli Lil­ly tasks Nim­bus with hit­ting a 'high-val­ue' tar­get for di­a­betes, obe­si­ty

3 years ago
Deals

PureTech, Nek­tar put an end to deal dis­cus­sions, cit­ing too much 'uncer­tain­ty'

3 years ago
Deals

Im­mat­ics spot­lights more ear­ly da­ta for TCR cell ther­a­py in sol­id tu­mors — now let's see if it lasts

3 years ago
R&D
Cell/Gene Tx

The crown jew­el in Mer­ck’s $11.5B Ac­celeron buy­out just cleared a piv­otal PhI­II

3 years ago
R&D

Taste of M&A Mon­day; A spe­cial kind of lab; Biotech founder wins No­bel; Bio­Marin lay­offs; and more

3 years ago
Weekly

Math­ai Mam­men emerges as top can­di­date for Bio­gen CEO job — STAT

3 years ago
People

On­colyt­ic virus ex­perts at Replimune re­load with $200M loan as biotech col­lects clin­i­cal da­ta

3 years ago
Financing

Bio­Marin lays off 120 staffers to 'sim­pli­fy' the com­pa­ny while FDA re­views its big gene ther­a­py

3 years ago
People

Ris­ing from the IL-2 ash­es and dras­tic re­org, Nek­tar in merg­er talks with PureTech

3 years ago
Deals
First page Previous page 22232425262728 Next page Last page
A service from the Financial Times